- Email: [email protected]
5429821 Non-fibrogenic high mannuronate aliginate coated transplants, processes for their manufacture and methods for their use
V
PatentsALERT
Proteolytic enzyme compositions and processes for digesting connective tissue are provided. The enzyme compositions include collagenase, which is essentially free of toxins and non-collagen specific components, and chymopapain, which is essentially free of toxins. The enzyme compositions are used for dissociating microvessel cells from connective tissue. Recovered microvessel cells are incorporated into artificial vessel grafts. The composition preferrably contains collagenase having an activity of about 43 x&at/ml to about 51 r&at/ml and chymopapin having an activity of about 0.22 r&at/ml to about 0.44 t&at/ml.
cells. Fish serum is used together with designated defined media to allow mammalian cells to grow and populations of these cells to be maintained. Blood serum is derived from captive stocks of fish raised under controlled conditions such that the diet, habitat, genetics, life history, and reproductive status of the fish remains substantially consistent and reproducible.
5426098 5425764 BIOARTIFICIAL PANCREAS Foumier Ronald; Goldblatt Peter; Horner James M; Sarver Jeffrey Sylvania, OH, UNITED STATES Assigned to The University of Toledo An implantable bioartificial pancreas device having an islet chamber containing glucose responsive and insulin-secreting islets of Langerhans or similar hormone secreting cells, one or more vascularizing chambers open to surrounding tissue, a semipermeable membrane between the islet and vascularizing chambers that allows passage of small molecules including insulin, oxygen and glucose and does not allow passage of agents of the immune system such as white cells and antibodies, the vascularizing chambers containing a growth factor soaked fibrous or foam matrix having a porosity of about 40 to 95%, the matrix nroviding small capillary growth and preventing ‘the blood from clotting in the lower chamber.
INCREASE IN HEMATOPOIETIC PROGENITOR CELLS IN PERIPHERAL BLOOD BY TRANSFORMING GROWTH FACTOR BETA San Leandro, CA, UNITED Carlino Joseph A STATES Assigned to Celtrix Pharmaceuticals Inc TGF beta is used to increase the numbers of stem cells in a subject’s peripheral blood. Then the subject’s blood is drawn and the stem cells removed. After myelosuppressive therapy is administered to the subject, the stem cells are administered to the subject. An alternate method provides for TGF beta administration to a donor subject whose blood is drawn and from whose blood the stem cells are removed; after a recipient subject receives myelosuppressive therapy, the stem cells are administered to the recipient subject.
5429821 5426045 METHOD FOR CULTURING MAMMALIAN CELLS IN A MEDIUM CONTAINING FISH SERUM Sawyer Evelyn; ME, UNITED Holdings Inc
Sawyer Philip Kennebunkport, STATES Assigned to Sea Run
A method for culturing mammalian cells using fish serum. The method uses serum extracted from the blood of fishes to culture mammalian cells for various purposes. The technique has the key advantages of 1) freedom from , mammalian infectious agents that could contaminate cell lines or endanger researchers or recipients of therapeutants derived from mammalian cell culture; 2) consistent and reproducible serum content and quality; 3) low cross-reactivity; and 4) the appropriate serum nutrients to maintain the growth of mammalian
NON-FIBROGENIC HIGH MANNURONATE ALIGINATE COATED TRANSPLANTS, PROCESSES FOR THEIR MANUFACTURE AND METHODS FOR THEIR USE Doria Randel E; Cochrum Kent C; Jemtrud Susan A Orinda, CA, UNITED STATES Assigned to The Regents of the University of California A transplant comprising a core of a viable, physiologically active cells coated with a nonfibrogenic alkaline earth metal alginate free from fibrogenic amounts of fucose, sulfate, phloroglucinol and protein moieties, having a marmuronate to guluronate molar ratio of from 1.2 to 6. The coating protects the core from host immunological destruction after transplantation. The coating is sufficiently permeable to permit the diffusion of nutrients and cell products through the
VI
PatentsALERT
coating. A process for coating the transplant core comprising coating the core with alginate substantially free from fibrogenic compounds and reacting the alginate coating with alkaline earth metal cations comprising calcium ions or magnesium ions or mixture thereof to form an alkaline earth metal alginate coating.
5435999 PROLIFERATIVE ACTION OF LEUKAEMIA INHIBITORY FACTOR ON SATELLITE CELLS Austin Lawrenc Mount Waverley, Assigned to Monash University
5431896 MICROBIAL IMMUNOREGULANT Kaplan Louis; Borris Robert P; Byrne Kevin; Wicker Linda S; Zink Deborah L New City, NY, UNITED STATES Assigned to Merck & Co lnc Described is a new immunosuppressant, L-687,819, a C-31 demethylated derivative of L-683,795 (FK523), produced under fermentation conditions the new mutant microorganism, utilizing Streptomyces hygroscopicus subsp. ascomyceticus (Merck Culture Collection MA 6646) ATCC No. 53855, being a blocked mutant of Streptomyces hygroscopicus subsp. ascomyceticus (MA 6475) 14891. macrolide ATCC No. The immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
AUSTRALIA
PCT No. PCT/AU90/00556 Sec. 371 Date Aug. 12, 1991 Sec. 102(e) Date Aug. 12, 1991 PCT Filed Nov. 20, 1990 PCT Pub. No. WO91/07992 PCT Pub. Date Jun. 13, 1991. The present invention relates to the use of leukaemia inhibitory factor (LIF), alone or in combination with other cytokines such as interleukind (IL-6) and/or transforming growth factor alpha(TGF alpha) and/or fibroblast growth factor (FGF), to stimulate the proliferation and/or differentiation of mammalian cells. The present invention also satellite contemplates a method comprising myoblast transfer therapy whereby LIF, alone or in combination with is/are employed to proliferate other cytokines, and/or differentiate mammalian satellite cells into myoblasts. The present invention is also directed to a cell activating composition and a pharmaceutical comprising LIF alone or in composition combination with other cytokines to promote proliferation and/or differentiation of mammalian satellite cells in vitro and in vivo, respectively.
5433946
5436319
SYNTHESIS AND UTILIZATION OF THERAPEUTIC AGENTS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
CELL FREE T CELL ANTIGEN RECEPTOR BETA CHAIN AND ITS CLINICAL UTILITIES A to
Kung Patrick C; lp Stephen; Brown Michael C Cambridge, MA, UNITED STATES Assigned to T Cell Sciences lnc
The present invention provides compositions wherein endogenous lectins are used as transport vehicles for facilitating the cell-specific binding and cellular uptake of therapeutic agents useful in the treatment of lysosomal storage diseases. In accordance with one embodiment, lectin-glycosidase conjugates are provided for enzyme replacement therapy of cells containing deficient enzyme activity. In accordance with another embodiment, comprising lectin-nucleic acid compositions constructs are provided for gene therapy of cells containing deficient enzyme activity. A third embodiment of the present invention relates to lectin-oligonucleotide compositions provided for antisense therapy to modulate production of mutant and defective lysosomal enzymes.
Cell-free or released T cell antigen receptors, immunoassays which allow the detection of the released T cell antigen receptor in cell culture supematants, cell lysates, and biological fluids, as well as diagnostic and therapeutic compositions and methods for monitoring and treating certain diseases or disorders which elicit or involve a T cell response are described. The released T cell antigen receptors described herein differ from the cell membrane bound antigen receptors and appear to exist in a variety of forms, some of which may be complexed with other T cell determinants such as the T3 antigen, Despite the size heterogeneity of the antigen receptors or cell released T receptor/complexes, these may be reliably identified using anti-receptor antibodies, including, but not limited to, anti-major framework, anti-minor
DiCioccio Richard Howard J; Allen Tonawanda, NY, UNITED STATES Assigned Health Research lnc
PatentsALERT
Proteolytic enzyme compositions and processes for digesting connective tissue are provided. The enzyme compositions include collagenase, which is essentially free of toxins and non-collagen specific components, and chymopapain, which is essentially free of toxins. The enzyme compositions are used for dissociating microvessel cells from connective tissue. Recovered microvessel cells are incorporated into artificial vessel grafts. The composition preferrably contains collagenase having an activity of about 43 x&at/ml to about 51 r&at/ml and chymopapin having an activity of about 0.22 r&at/ml to about 0.44 t&at/ml.
cells. Fish serum is used together with designated defined media to allow mammalian cells to grow and populations of these cells to be maintained. Blood serum is derived from captive stocks of fish raised under controlled conditions such that the diet, habitat, genetics, life history, and reproductive status of the fish remains substantially consistent and reproducible.
5426098 5425764 BIOARTIFICIAL PANCREAS Foumier Ronald; Goldblatt Peter; Horner James M; Sarver Jeffrey Sylvania, OH, UNITED STATES Assigned to The University of Toledo An implantable bioartificial pancreas device having an islet chamber containing glucose responsive and insulin-secreting islets of Langerhans or similar hormone secreting cells, one or more vascularizing chambers open to surrounding tissue, a semipermeable membrane between the islet and vascularizing chambers that allows passage of small molecules including insulin, oxygen and glucose and does not allow passage of agents of the immune system such as white cells and antibodies, the vascularizing chambers containing a growth factor soaked fibrous or foam matrix having a porosity of about 40 to 95%, the matrix nroviding small capillary growth and preventing ‘the blood from clotting in the lower chamber.
INCREASE IN HEMATOPOIETIC PROGENITOR CELLS IN PERIPHERAL BLOOD BY TRANSFORMING GROWTH FACTOR BETA San Leandro, CA, UNITED Carlino Joseph A STATES Assigned to Celtrix Pharmaceuticals Inc TGF beta is used to increase the numbers of stem cells in a subject’s peripheral blood. Then the subject’s blood is drawn and the stem cells removed. After myelosuppressive therapy is administered to the subject, the stem cells are administered to the subject. An alternate method provides for TGF beta administration to a donor subject whose blood is drawn and from whose blood the stem cells are removed; after a recipient subject receives myelosuppressive therapy, the stem cells are administered to the recipient subject.
5429821 5426045 METHOD FOR CULTURING MAMMALIAN CELLS IN A MEDIUM CONTAINING FISH SERUM Sawyer Evelyn; ME, UNITED Holdings Inc
Sawyer Philip Kennebunkport, STATES Assigned to Sea Run
A method for culturing mammalian cells using fish serum. The method uses serum extracted from the blood of fishes to culture mammalian cells for various purposes. The technique has the key advantages of 1) freedom from , mammalian infectious agents that could contaminate cell lines or endanger researchers or recipients of therapeutants derived from mammalian cell culture; 2) consistent and reproducible serum content and quality; 3) low cross-reactivity; and 4) the appropriate serum nutrients to maintain the growth of mammalian
NON-FIBROGENIC HIGH MANNURONATE ALIGINATE COATED TRANSPLANTS, PROCESSES FOR THEIR MANUFACTURE AND METHODS FOR THEIR USE Doria Randel E; Cochrum Kent C; Jemtrud Susan A Orinda, CA, UNITED STATES Assigned to The Regents of the University of California A transplant comprising a core of a viable, physiologically active cells coated with a nonfibrogenic alkaline earth metal alginate free from fibrogenic amounts of fucose, sulfate, phloroglucinol and protein moieties, having a marmuronate to guluronate molar ratio of from 1.2 to 6. The coating protects the core from host immunological destruction after transplantation. The coating is sufficiently permeable to permit the diffusion of nutrients and cell products through the
VI
PatentsALERT
coating. A process for coating the transplant core comprising coating the core with alginate substantially free from fibrogenic compounds and reacting the alginate coating with alkaline earth metal cations comprising calcium ions or magnesium ions or mixture thereof to form an alkaline earth metal alginate coating.
5435999 PROLIFERATIVE ACTION OF LEUKAEMIA INHIBITORY FACTOR ON SATELLITE CELLS Austin Lawrenc Mount Waverley, Assigned to Monash University
5431896 MICROBIAL IMMUNOREGULANT Kaplan Louis; Borris Robert P; Byrne Kevin; Wicker Linda S; Zink Deborah L New City, NY, UNITED STATES Assigned to Merck & Co lnc Described is a new immunosuppressant, L-687,819, a C-31 demethylated derivative of L-683,795 (FK523), produced under fermentation conditions the new mutant microorganism, utilizing Streptomyces hygroscopicus subsp. ascomyceticus (Merck Culture Collection MA 6646) ATCC No. 53855, being a blocked mutant of Streptomyces hygroscopicus subsp. ascomyceticus (MA 6475) 14891. macrolide ATCC No. The immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
AUSTRALIA
PCT No. PCT/AU90/00556 Sec. 371 Date Aug. 12, 1991 Sec. 102(e) Date Aug. 12, 1991 PCT Filed Nov. 20, 1990 PCT Pub. No. WO91/07992 PCT Pub. Date Jun. 13, 1991. The present invention relates to the use of leukaemia inhibitory factor (LIF), alone or in combination with other cytokines such as interleukind (IL-6) and/or transforming growth factor alpha(TGF alpha) and/or fibroblast growth factor (FGF), to stimulate the proliferation and/or differentiation of mammalian cells. The present invention also satellite contemplates a method comprising myoblast transfer therapy whereby LIF, alone or in combination with is/are employed to proliferate other cytokines, and/or differentiate mammalian satellite cells into myoblasts. The present invention is also directed to a cell activating composition and a pharmaceutical comprising LIF alone or in composition combination with other cytokines to promote proliferation and/or differentiation of mammalian satellite cells in vitro and in vivo, respectively.
5433946
5436319
SYNTHESIS AND UTILIZATION OF THERAPEUTIC AGENTS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
CELL FREE T CELL ANTIGEN RECEPTOR BETA CHAIN AND ITS CLINICAL UTILITIES A to
Kung Patrick C; lp Stephen; Brown Michael C Cambridge, MA, UNITED STATES Assigned to T Cell Sciences lnc
The present invention provides compositions wherein endogenous lectins are used as transport vehicles for facilitating the cell-specific binding and cellular uptake of therapeutic agents useful in the treatment of lysosomal storage diseases. In accordance with one embodiment, lectin-glycosidase conjugates are provided for enzyme replacement therapy of cells containing deficient enzyme activity. In accordance with another embodiment, comprising lectin-nucleic acid compositions constructs are provided for gene therapy of cells containing deficient enzyme activity. A third embodiment of the present invention relates to lectin-oligonucleotide compositions provided for antisense therapy to modulate production of mutant and defective lysosomal enzymes.
Cell-free or released T cell antigen receptors, immunoassays which allow the detection of the released T cell antigen receptor in cell culture supematants, cell lysates, and biological fluids, as well as diagnostic and therapeutic compositions and methods for monitoring and treating certain diseases or disorders which elicit or involve a T cell response are described. The released T cell antigen receptors described herein differ from the cell membrane bound antigen receptors and appear to exist in a variety of forms, some of which may be complexed with other T cell determinants such as the T3 antigen, Despite the size heterogeneity of the antigen receptors or cell released T receptor/complexes, these may be reliably identified using anti-receptor antibodies, including, but not limited to, anti-major framework, anti-minor
DiCioccio Richard Howard J; Allen Tonawanda, NY, UNITED STATES Assigned Health Research lnc